marketcaparena
Search

    BMRN

    BIOMARIN PHARMACEUTICAL INC

    Company overview

    Market capitalization
    $11.51B
    Employees
    3,221
    Latest publication
    2026-09-29
    About BIOMARIN PHARMACEUTICAL INC

    BioMarin Pharmaceutical Inc., a biotechnology company, engages in the development and commercialization of therapies for life-threatening rare diseases and medical conditions in the United States, Europe, Latin America, the Middle East, the Asia Pacific, and internationally. The company's products include VIMIZIM, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; VOXZOGO, a once daily injection analog of c-type natriuretic peptide (CNP) for the treatment of achondroplasia; NAGLAZYME, a recombinant form of N- acetylgalactosamine 4-sulfatase for patients with MPS VI; and PALYNZIQ, a PEGylated recombinant phenylalanine (Phe) ammonia lyase enzyme delivered through subcutaneous injection to reduce blood Phe concentrations. It also develops BRINEURA, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; ALDURAZYME, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase; and KUVAN, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria, an inherited metabolic disease. The company's products under development include BMN 333, a longer-acting CNP for the treatment of multiple growth disorders, such as achondroplasia and hypochondroplasia; and BMN 351, an oligonucleotide for the treatment of duchenne muscular dystrophy. It serves specialty pharmacies, hospitals, non-U.S. government agencies, distributors, and pharmaceutical wholesalers. The company has license and collaboration agreements with and Ares Trading S.A. The company was incorporated in 1996 and is based in San Rafael, California.

    Company website

    Financial statements

    Income Quarterly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricQ2 20262026-06-30 · USDQ1 20262026-03-31 · USDQ4 20252025-12-31 · USDQ2 20252025-06-30 · USDQ1 20252025-03-31 · USDQ4 20242024-12-31 · USDQ3 20242024-09-30 · USDQ2 20242024-06-30 · USD
    Total Revenue989,708,000USD766,208,000USD874,565,000USD825,410,000USD745,145,000USD747,313,000USD745,740,000USD712,029,000USD
    Cost Of Revenue202,795,000USD194,999,000USD295,095,000USD150,090,000USD151,558,000USD136,139,000USD188,457,000USD130,459,000USD
    Gross Profit786,913,000USD571,209,000USD579,470,000USD675,320,000USD593,587,000USD611,174,000USD557,283,000USD581,570,000USD
    Research Development206,952,000USD178,796,000USD192,413,000USD161,308,000USD158,731,000USD173,509,000USD184,901,000USD183,787,000USD
    Selling General Administrative395,549,000USD133,400,000USD802,117,000USD110,200,000USD103,600,000USD141,000,000USD144,600,000USD140,200,000USD
    Total Operating Expenses675,993,000USD441,579,000USD500,080,000USD398,433,000USD369,694,000USD449,767,000USD443,390,000USD461,118,000USD
    Operating Income110,920,000USD129,630,000USD79,389,999USD276,887,000USD223,893,000USD161,407,000USD113,893,000USD120,452,000USD
    Total Other Income Expense Net-49,536,000USD11,573,000USD-106,542,999USD20,981,000USD14,196,000USD8,232,000USD20,548,000USD11,684,000USD
    Interest Income10,480,000USD22,560,000USD19,210,000USD18,827,000USD19,013,000USD17,680,000USD18,053,000USD19,785,000USD
    Interest Expense63,295,000USD14,958,000USD2,778,000USD2,679,000USD2,863,000USD2,577,000USD2,968,000USD3,574,000USD
    Income Before Tax61,384,000USD141,203,000USD-27,153,000USD297,868,000USD238,089,000USD169,639,000USD134,441,000USD132,136,000USD
    Income Tax Expense16,622,000USD35,676,000USD19,420,000USD57,336,000USD52,403,000USD44,696,000USD28,361,000USD24,962,000USD
    Net Income44,762,000USD105,527,000USD-46,573,000USD240,532,000USD185,686,000USD124,943,000USD106,080,000USD107,174,000USD
    Net Income Applicable To Common Shares44,762,000USD———————
    Selling And Marketing Expenses—124,900,000USD—122,100,000USD102,500,000USD125,600,000USD108,900,000USD122,800,000USD
    Unclassified Operating Expenses—4,483,000USD-494,450,000USD4,825,000USD4,863,000USD9,658,000USD4,989,000USD14,331,000USD
    Net Interest Income—7,602,000USD16,432,000USD16,148,000USD16,150,000USD15,039,000USD15,085,000USD16,211,000USD
    Tax Provision—35,676,000USD19,420,000USD57,336,000USD52,403,000USD44,696,000USD28,361,000USD24,962,000USD
    Net Income From Continuing Ops—105,527,000USD-46,573,000USD240,532,000USD185,686,000USD124,943,000USD106,080,000USD107,174,000USD
    Ebit—156,161,000USD-24,375,000USD300,547,000USD240,952,000USD171,889,000USD137,409,000USD135,710,000USD
    Ebitda—172,572,000USD-3,937,000USD319,110,000USD263,021,000USD195,496,000USD156,415,000USD162,173,000USD
    Depreciation And Amortization—16,411,000USD20,438,000USD18,563,000USD22,069,000USD23,607,000USD19,006,000USD26,463,000USD
    Reconciled Depreciation—16,411,000USD20,438,000USD18,563,000USD22,069,000USD23,607,000USD19,006,000USD26,463,000USD
    SourceDisclosureDeterministicFinalLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Income Yearly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricFY 20252025-12-31 · USDFY 20242024-12-31 · USDFY 20232023-12-31 · USDFY 20222022-12-31 · USDFY 20102010-12-31 · USDFY 20092009-12-31 · USDFY 20082008-12-31 · USDFY 20032003-12-31 · USD
    Total Revenue3,221,253,000USD2,853,915,000USD2,419,226,000USD2,096,039,000USD376,267,000USD324,656,000USD296,493,000USD12,100,000USD
    Cost Of Revenue736,828,000USD580,235,000USD532,062,000USD503,023,000USD70,285,000USD65,909,000USD52,509,000USD62,212,000USD
    Gross Profit2,484,425,000USD2,273,680,000USD1,887,164,000USD1,593,016,000USD305,982,000USD258,747,000USD243,984,000USD12,100,000USD
    Research Development921,930,000USD747,184,000USD746,773,000USD649,606,000USD147,309,000USD115,116,000USD93,291,000USD54,814,000USD
    Selling General Administrative1,153,017,000USD532,300,000USD404,000,000USD372,900,000USD151,723,000USD124,290,000USD106,566,000USD14,396,000USD
    Unclassified Operating Expenses-124,000,000USD33,282,000USD62,217,000USD409,536,000USD6,406,000USD2,914,000USD4,371,000USD18,693,000USD
    Total Operating Expenses1,950,947,000USD1,789,466,000USD1,701,390,000USD1,432,042,000USD305,438,000USD242,320,000USD204,228,000USD87,903,000USD
    Operating Income533,477,999USD484,214,000USD185,774,000USD160,974,000USD544,000USD16,427,000USD39,756,000USD-75,803,000USD
    Interest Income74,904,000USD74,883,000USD49,005,000USD18,034,000USD————
    Interest Expense10,899,000USD12,666,000USD17,335,000USD15,970,000USD10,329,000USD14,090,000USD16,394,000USD3,131,000USD
    Net Interest Income64,005,000USD62,153,000USD34,142,000USD2,064,000USD————
    Income Before Tax482,480,000USD541,763,000USD188,563,000USD149,576,000USD-21,490,000USD566,000USD33,424,000USD-75,798,000USD
    Income Tax Expense133,579,000USD114,904,000USD20,918,000USD8,015,000USD-227,309,000USD1,054,000USD2,593,000USD-5,000USD
    Tax Provision133,579,000USD114,904,000USD4,657,000USD8,015,000USD————
    Net Income348,901,000USD426,859,000USD167,645,000USD141,561,000USD205,819,000USD-488,000USD30,831,000USD-75,798,000USD
    Net Income From Continuing Ops348,901,000USD426,859,000USD147,021,000USD141,561,000USD205,819,000USD———
    Ebit493,379,000USD554,102,000USD202,387,000USD163,390,000USD-10,672,000USD14,656,000USD49,818,000USD-75,803,000USD
    Ebitda572,936,000USD650,528,000USD306,773,000USD265,359,000USD17,065,000USD35,631,000USD67,434,000USD-66,361,000USD
    Depreciation And Amortization79,557,000USD96,426,000USD104,386,000USD101,969,000USD27,737,000USD20,975,000USD17,616,000USD9,442,000USD
    Reconciled Depreciation79,557,000USD96,426,000USD102,078,000USD101,969,000USD————
    Total Other Income Expense Net-50,997,999USD57,549,000USD2,789,000USD-11,398,000USD-22,034,000USD-15,861,000USD-6,332,000USD75,803,000USD
    Selling And Marketing Expenses—476,700,000USD488,400,000USD—————
    Net Income Applicable To Common Shares———141,561,000USD205,819,000USD—30,831,000USD—
    Non Operating Income Net Other————-11,705,000USD———
    SourceLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Balance sheet Quarterly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricQ2 20262026-06-30 · USDQ1 20262026-03-31 · USDQ4 20252025-12-31 · USDQ3 20252025-09-30 · USDQ2 20252025-06-30 · USDQ1 20252025-03-31 · USDQ4 20242024-12-31 · USDQ3 20242024-09-30 · USD
    Total Assets11,723,442,000USD8,591,016,000USD7,594,022,000USD7,614,868,000USD7,456,341,000USD7,147,007,000USD6,988,940,000USD6,851,195,000USD
    Cash And Equivalents874,005,000USD———————
    Total Current Assets3,971,623,000USD4,605,070,000USD3,953,490,000USD3,854,543,000USD3,805,332,000USD3,467,905,000USD3,232,427,000USD3,056,590,000USD
    Other Current Assets254,047,000USD205,500,000USD185,784,000USD204,265,000USD177,183,000USD181,545,000USD201,533,000USD169,260,000USD
    Other Non Current Assets338,138,000USD———————
    Total Liabilities5,401,750,000USD———————
    Total Current Liabilities1,663,996,000USD793,152,000USD759,031,000USD798,438,000USD684,247,000USD628,213,000USD606,988,000USD715,658,000USD
    Other Non Current Liabilities209,815,000USD———————
    Total Stockholder Equity6,321,692,000USD6,212,107,000USD6,086,999,000USD6,056,711,000USD6,027,113,000USD5,793,459,000USD5,657,990,000USD5,413,396,000USD
    Total Equity Including Noncontrolling Interest6,321,692,000USD———————
    Short Long Term Debt658,203,000USD———————
    Long Term Debt3,527,939,000USD1,430,282,000USD597,176,000USD596,663,000USD596,162,000USD595,650,000USD595,138,000USD594,627,000USD
    Net Receivables1,061,047,000USD903,914,000USD908,214,000USD790,266,000USD855,855,000USD739,177,000USD660,535,000USD777,547,000USD
    Inventory1,782,524,000USD1,273,221,000USD1,298,883,000USD1,382,173,000USD1,340,169,000USD1,274,848,000USD1,232,653,000USD1,179,339,000USD
    Property Plant Equipment Net989,994,000USD958,071,000USD952,508,000USD1,038,187,000USD1,030,385,000USD1,032,613,000USD1,043,041,000USD1,045,408,000USD
    Goodwill655,745,000USD———————
    Intangible Assets4,879,367,000USD204,662,000USD213,837,000USD233,112,000USD239,620,000USD247,346,000USD255,278,000USD260,920,000USD
    Accounts Payable1,005,793,000USD395,469,000USD312,768,000USD389,670,000USD310,797,000USD293,751,000USD235,403,000USD312,321,000USD
    Common Stock194,000USD193,000USD192,000USD192,000USD192,000USD192,000USD191,000USD191,000USD
    Retained Earnings304,495,000USD259,733,000USD154,206,000USD200,779,000USD231,523,000USD-9,009,000USD-194,695,000USD-319,638,000USD
    Accumulated Other Comprehensive Income-8,783,000USD-4,237,000USD-13,473,000USD-33,937,000USD-44,565,000USD19,151,000USD61,653,000USD4,650,000USD
    Total Liab—2,378,909,000USD1,507,023,000USD1,558,157,000USD1,429,228,000USD1,353,548,000USD1,330,950,000USD1,437,799,000USD
    Other Current Liab—388,364,000USD437,578,000USD401,190,000USD352,345,000USD304,211,000USD350,075,000USD371,891,000USD
    Capital Stock—193,000USD192,000USD192,000USD192,000USD192,000USD191,000USD191,000USD
    Good Will—196,199,000USD196,199,000USD196,199,000USD196,199,000USD196,199,000USD196,199,000USD196,199,000USD
    Cash—2,222,435,000USD1,311,679,000USD1,250,108,000USD1,213,816,000USD1,048,803,000USD942,842,000USD675,448,000USD
    Cash And Short Term Investments—2,222,435,000USD1,560,609,000USD1,477,839,000USD1,432,125,000USD1,272,335,000USD1,137,706,000USD930,444,000USD
    Net Debt—-782,834,000USD-668,806,000USD-645,867,000USD-609,950,000USD-446,844,000USD-340,130,000USD-72,761,000USD
    Short Term Debt—9,319,000USD8,685,000USD7,578,000USD7,704,000USD6,309,000USD7,574,000USD8,060,000USD
    Short Long Term Debt Total—1,439,601,000USD642,873,000USD604,241,000USD603,866,000USD601,959,000USD602,712,000USD602,687,000USD
    Long Term Investments—0USD492,242,000USD512,937,000USD508,592,000USD506,724,000USD521,238,000USD561,985,000USD
    Short Term Investments—0USD248,930,000USD227,731,000USD218,309,000USD223,532,000USD194,864,000USD254,996,000USD
    Property Plant Equipment Gross—2,052,351,000USD2,026,813,000USD1,987,843,000USD1,961,407,000USD1,940,801,000USD1,934,832,000USD1,914,616,000USD
    Common Stock Shares Outstanding—197,671,000shares197,394,000shares192,032,000shares196,643,000shares196,474,000shares196,581,000shares197,147,000shares
    Non Current Assets Total—3,985,946,000USD3,640,532,000USD3,760,325,000USD3,651,009,000USD3,679,102,000USD3,756,513,000USD3,794,605,000USD
    Non Current Liabilities Total—1,585,757,000USD747,992,000USD759,719,000USD744,981,000USD725,335,000USD723,962,000USD722,141,000USD
    Non Current Liabilities Other—155,475,000USD150,816,000USD163,056,000USD148,819,000USD129,685,000USD128,824,000USD127,514,000USD
    Non Currrent Assets Other—268,751,000USD277,049,000USD270,781,000USD249,192,000USD235,654,000USD251,391,000USD199,314,000USD
    Net Working Capital—3,811,918,000USD3,194,459,000USD3,056,105,000USD3,121,085,000USD2,839,692,000USD2,625,439,000USD2,340,932,000USD
    Unclassified Non Current Assets—2,358,263,000USD1,508,697,000USD1,509,109,000USD1,427,021,000USD1,460,566,000USD1,489,366,000USD1,530,779,000USD
    Unclassified Equity—5,956,225,000USD5,945,882,000USD5,889,485,000USD5,839,771,000USD5,782,933,000USD5,790,650,000USD5,728,002,000USD
    Unclassified Current Liabilities————13,401,000USD23,942,000USD12,567,000USD21,040,000USD
    Current Deferred Revenue——————1,369,000USD2,346,000USD
    SourceDisclosureDeterministicFinalLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Balance sheet Yearly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricFY 20252025-12-31 · USDFY 20242024-12-31 · USDFY 20232023-12-31 · USDFY 20222022-12-31 · USDFY 20212021-12-31 · USDFY 20202020-12-31 · USDFY 20192019-12-31 · USDFY 20182018-12-31 · USD
    Total Assets7,594,022,000USD6,988,940,000USD6,841,603,000USD6,375,074,000USD6,003,325,000USD5,848,020,000USD4,690,039,000USD4,427,128,000USD
    Intangible Assets213,837,000USD255,278,000USD294,701,000USD338,569,000USD388,652,000USD417,271,000USD456,580,000USD491,808,000USD
    Other Current Assets185,784,000USD201,533,000USD141,391,000USD104,521,000USD110,442,000USD129,934,000USD130,657,000USD98,403,000USD
    Total Liab1,507,023,000USD1,330,950,000USD1,890,054,000USD1,771,918,000USD1,732,585,000USD1,742,018,000USD1,567,658,000USD1,459,188,000USD
    Total Stockholder Equity6,086,999,000USD5,657,990,000USD4,951,549,000USD4,603,156,000USD4,270,740,000USD4,106,002,000USD3,122,381,000USD2,967,940,000USD
    Other Current Liab437,578,000USD334,578,000USD351,588,000USD330,347,000USD329,399,000USD289,213,000USD294,313,000USD306,369,000USD
    Common Stock192,000USD191,000USD189,000USD186,000USD184,000USD182,000USD180,000USD178,000USD
    Capital Stock192,000USD191,000USD189,000USD186,000USD184,000USD182,000USD180,000USD178,000USD
    Retained Earnings154,206,000USD-194,695,000USD-621,554,000USD-789,199,000USD-925,689,000USD-861,609,000USD-1,720,709,000USD-1,694,134,000USD
    Good Will196,199,000USD196,199,000USD196,199,000USD196,199,000USD196,199,000USD196,199,000USD197,039,000USD197,039,000USD
    Cash1,311,679,000USD942,842,000USD755,127,000USD724,531,000USD587,276,000USD649,158,000USD437,446,000USD493,982,000USD
    Cash And Short Term Investments1,560,609,000USD1,137,706,000USD1,073,810,000USD1,291,537,000USD1,013,875,000USD1,065,386,000USD753,807,000USD1,084,308,000USD
    Total Current Assets3,953,490,000USD3,232,427,000USD2,956,088,000USD2,751,457,000USD2,274,385,000USD2,342,219,000USD1,942,143,000USD2,056,215,000USD
    Total Current Liabilities759,031,000USD606,988,000USD1,177,024,000USD588,884,000USD539,822,000USD492,548,000USD932,503,000USD523,241,000USD
    Net Debt-668,806,000USD-293,376,000USD340,624,000USD368,863,000USD491,801,000USD425,987,000USD421,374,000USD336,435,000USD
    Short Term Debt8,685,000USD23,071,000USD502,656,000USD10,375,000USD10,464,000USD11,754,000USD372,582,000USD—
    Short Long Term Debt Total642,873,000USD649,466,000USD1,095,751,000USD1,093,394,000USD1,089,541,000USD1,086,899,000USD858,820,000USD830,417,000USD
    Long Term Debt597,176,000USD595,138,000USD593,095,000USD1,083,019,000USD1,079,077,000USD1,075,145,000USD486,238,000USD830,417,000USD
    Long Term Investments492,242,000USD521,238,000USD611,135,000USD333,835,000USD507,793,000USD285,473,000USD411,978,000USD235,864,000USD
    Short Term Investments248,930,000USD194,864,000USD318,683,000USD567,006,000USD426,599,000USD416,228,000USD316,361,000USD590,326,000USD
    Net Receivables908,214,000USD660,535,000USD633,704,000USD461,316,000USD373,399,000USD448,351,000USD377,404,000USD342,633,000USD
    Inventory1,298,883,000USD1,232,653,000USD1,107,183,000USD894,083,000USD776,669,000USD698,548,000USD680,275,000USD530,871,000USD
    Accounts Payable312,768,000USD235,403,000USD315,509,000USD231,238,000USD193,003,000USD191,429,000USD240,981,000USD207,620,000USD
    Property Plant Equipment Net952,508,000USD1,043,041,000USD1,066,133,000USD1,073,366,000USD1,035,461,000USD1,032,471,000USD1,010,868,000USD948,682,000USD
    Property Plant Equipment Gross2,026,813,000USD1,934,832,000USD1,933,222,000USD1,875,511,000USD1,756,035,000USD1,032,471,000USD1,010,868,000USD948,682,000USD
    Accumulated Other Comprehensive Income-13,473,000USD61,653,000USD-28,788,000USD-3,867,000USD14,432,000USD-16,139,000USD20,164,000USD5,271,000USD
    Common Stock Shares Outstanding197,394,000shares196,708,000shares191,595,000shares188,963,000shares182,852,000shares191,678,000shares179,039,000shares177,268,000shares
    Non Current Assets Total3,640,532,000USD3,756,513,000USD3,885,515,000USD3,623,617,000USD3,728,940,000USD3,505,801,000USD2,747,896,000USD2,370,913,000USD
    Non Current Liabilities Total747,992,000USD723,962,000USD713,030,000USD1,183,034,000USD1,192,763,000USD1,249,470,000USD635,155,000USD935,947,000USD
    Non Current Liabilities Other150,816,000USD128,824,000USD119,935,000USD100,015,000USD113,686,000USD174,325,000USD148,917,000USD105,530,000USD
    Non Currrent Assets Other277,049,000USD251,391,000USD171,538,000USD176,236,000USD151,760,000USD142,237,000USD122,009,000USD36,568,000USD
    Net Working Capital3,194,459,000USD2,625,439,000USD1,779,064,000USD2,162,573,000USD1,734,563,000USD1,849,671,000USD1,009,640,000USD1,532,974,000USD
    Unclassified Non Current Assets1,508,697,000USD1,489,366,000USD1,545,809,000USD-98,780,000USD-151,760,000USD-142,237,000USD-62,575,000USD-35,626,000USD
    Unclassified Equity5,945,882,000USD5,790,650,000USD5,601,513,000USD5,395,850,000USD5,181,629,000USD4,983,386,000USD4,822,566,000USD4,656,447,000USD
    Current Deferred Revenue—1,369,000USD4,620,000USD711,000USD6,956,000USD152,000USD13,037,000USD1,467,000USD
    Unclassified Current Liabilities—12,567,000USD-491,226,000USD16,213,000USD——-350,292,000USD7,785,000USD
    Short Long Term Debt——493,877,000USD———361,882,000USD—
    Other Liab———73,502,000USD113,686,000USD174,325,000USD98,117,000USD105,530,000USD
    Other Assets———1,604,192,000USD1,600,835,000USD1,574,387,000USD611,997,000USD496,578,000USD
    Net Tangible Assets———4,068,388,000USD3,685,889,000USD3,492,532,000USD2,468,762,000USD2,279,093,000USD
    Unclassified Non Current Liabilities———-73,502,000USD-113,686,000USD-174,325,000USD-98,117,000USD-105,530,000USD
    SourceLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Cash flow YTD

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricQ2 20262026-06-30 · USD
    Depreciation114,049,000USD
    Stock Based Compensation119,152,000USD
    Deferred Income Tax2,261,000USD
    Other Non Cash Items5,534,000USD
    Change To Account Receivables-46,005,000USD
    Change To Inventory12,334,000USD
    Change To Liabilities32,932,000USD
    Change In Working Capital8,266,000USD
    Operating Cash Flow388,760,000USD
    Capital Expenditures-49,739,000USD
    Net Investments741,485,000USD
    Other Investing Activities-4,966,000USD
    Unclassified Investing Cash Flow-5,063,131,000USD
    Investing Cash Flow-4,376,351,000USD
    Net Debt Issuance3,650,000,000USD
    Common Stock Issuance6,655,000USD
    Net Common Stock Issuance-39,504,000USD
    Unclassified Financing Cash Flow-65,604,000USD
    Financing Cash Flow3,551,547,000USD
    Effect Of Forex Changes On Cash-1,630,000USD
    Change In Cash-437,674,000USD
    End Cash Flow874,005,000USD
    SourceDisclosureDeterministicFinal

    Cash flow Quarterly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricQ1 20262026-03-31 · USDQ3 20252025-09-30 · USDQ1 20252025-03-31 · USDQ4 20242024-12-31 · USDQ3 20242024-09-30 · USDQ2 20242024-06-30 · USDQ1 20242024-03-31 · USDQ4 20232023-12-31 · USD
    Net Income105,527,000USD-30,744,000USD185,686,000USD124,943,000USD106,080,000USD107,174,000USD88,662,000USD20,375,000USD
    Depreciation16,411,000USD18,487,000USD22,069,000USD23,607,000USD19,006,000USD26,463,000USD27,350,000USD26,861,000USD
    Stock Based Compensation43,458,000USD49,265,000USD37,700,000USD51,919,000USD43,489,000USD47,914,000USD58,249,000USD54,855,000USD
    Other Non Cash Items6,967,000USD226,396,000USD-9,028,000USD25,922,000USD1,672,000USD2,880,000USD-22,189,000USD47,352,000USD
    Change To Account Receivables-7,159,000USD48,746,000USD-57,590,000USD72,547,000USD-74,375,000USD-52,695,000USD-3,386,000USD-58,495,000USD
    Change To Inventory44,490,000USD-26,334,000USD-24,335,000USD-34,271,000USD18,150,000USD-30,589,000USD-16,820,000USD-59,110,000USD
    Change In Working Capital39,068,000USD118,927,000USD-90,462,000USD-83,151,000USD39,062,000USD-66,921,000USD-105,386,000USD-97,116,000USD
    Total Cash From Operating Activities220,651,000USD368,685,000USD174,394,000USD185,627,000USD221,481,000USD118,762,000USD46,971,000USD27,483,000USD
    Capital Expenditures-20,923,000USD-28,447,000USD-16,768,000USD-20,299,000USD-21,176,000USD-21,839,000USD-34,104,000USD-36,696,000USD
    Free Cash Flow199,728,000USD340,238,000USD157,626,000USD165,328,000USD200,305,000USD96,923,000USD12,867,000USD-9,213,000USD
    Investments741,485,000USD-330,963,000USD-28,238,000USD76,404,000USD-16,157,000USD90,480,000USD-14,236,000USD-64,963,000USD
    Total Cashflows From Investing Activities725,528,000USD-330,963,000USD-28,238,000USD76,404,000USD-16,157,000USD90,480,000USD-14,236,000USD-64,963,000USD
    Net Borrowings850,000,000USD—0USD0USD-494,927,000USD———
    Total Cash From Financing Activities813,167,000USD-2,169,000USD-38,779,000USD2,859,000USD-499,125,000USD12,612,000USD-42,793,000USD10,840,000USD
    Sale Purchase Of Stock-28,180,000USD-38,779,000USD-38,779,000USD-4,909,000USD-5,912,000USD-16,791,000USD-49,948,000USD-3,920,000USD
    Change In Cash1,760,756,000USD36,292,000USD105,961,000USD267,394,000USD-296,702,000USD225,154,000USD-8,131,000USD-30,287,000USD
    Begin Period Cash Flow1,311,679,000USD1,213,816,000USD942,842,000USD675,448,000USD972,150,000USD746,996,000USD755,127,000USD785,414,000USD
    End Period Cash Flow3,072,435,000USD1,250,108,000USD1,048,803,000USD942,842,000USD675,448,000USD972,150,000USD746,996,000USD755,127,000USD
    Other Cashflows From Investing Activities4,966,000USD-2,368,000USD—-769,000USD-1,572,000USD-512,000USD2,000,000USD-7,779,000USD
    Other Cashflows From Financing Activities-8,653,000USD-2,176,000USD-38,779,000USD-5,003,000USD-4,198,000USD12,630,000USD-42,751,000USD-3,920,000USD
    Unclassified Operating Cash Flow9,220,000USD-13,646,000USD28,429,000USD42,387,000USD12,172,000USD1,252,000USD—-24,844,000USD
    Unclassified Investing Cash Flow—30,815,000USD16,768,000USD21,068,000USD22,748,000USD22,351,000USD32,104,000USD44,475,000USD
    Unclassified Financing Cash Flow—38,786,000USD38,779,000USD12,771,000USD5,912,000USD16,773,000USD49,906,000USD18,680,000USD
    SourceLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Cash flow Yearly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricFY 20252025-12-31 · USDFY 20242024-12-31 · USDFY 20232023-12-31 · USDFY 20222022-12-31 · USDFY 20212021-12-31 · USDFY 20202020-12-31 · USDFY 20192019-12-31 · USDFY 20182018-12-31 · USD
    Net Income348,901,000USD426,859,000USD167,645,000USD141,561,000USD-64,080,000USD859,100,000USD-23,848,000USD-77,211,000USD
    Depreciation79,557,000USD96,426,000USD104,386,000USD101,969,000USD108,039,000USD105,172,000USD105,300,000USD95,671,000USD
    Stock Based Compensation181,409,000USD201,571,000USD207,099,000USD196,308,000USD197,263,000USD189,711,000USD159,865,000USD148,819,000USD
    Other Non Cash Items278,071,000USD8,285,000USD61,649,000USD-115,466,000USD12,888,000USD44,706,000USD-9,203,000USD-29,273,000USD
    Change To Account Receivables-228,054,000USD-57,909,000USD-190,435,000USD-82,033,000USD65,574,000USD-59,035,000USD-37,852,000USD-54,274,000USD
    Change To Inventory119,208,000USD-63,530,000USD-157,058,000USD-68,264,000USD-35,060,000USD-61,151,000USD-107,554,000USD-23,747,000USD
    Change In Working Capital-108,682,000USD-216,396,000USD-336,539,000USD-96,383,000USD66,034,000USD-224,417,000USD-101,092,000USD-49,420,000USD
    Total Cash From Operating Activities827,994,000USD572,841,000USD159,259,000USD175,902,000USD304,536,000USD85,365,000USD48,262,000USD20,208,000USD
    Capital Expenditures-103,038,000USD-97,418,000USD-107,611,000USD-120,959,000USD-119,225,000USD-137,519,000USD-145,026,000USD-144,620,000USD
    Free Cash Flow724,956,000USD475,423,000USD51,648,000USD54,943,000USD185,311,000USD-52,154,000USD-96,764,000USD-124,412,000USD
    Investments-18,074,000USD136,491,000USD-100,991,000USD-20,029,000USD-366,313,000USD26,171,000USD108,188,000USD358,981,000USD
    Total Cashflows From Investing Activities-414,242,000USD136,491,000USD-111,244,000USD-20,029,000USD-366,313,000USD-53,621,000USD-31,026,000USD264,351,000USD
    Net Borrowings0USD-494,987,000USD0USD-2,605,000USD-3,039,000USD210,761,000USD-5,087,000USD-374,953,000USD
    Total Cash From Financing Activities-42,394,000USD-526,447,000USD-18,727,000USD-18,650,000USD-48,000USD181,118,000USD-74,674,000USD-388,007,000USD
    Change In Cash368,837,000USD187,715,000USD30,596,000USD137,255,000USD-61,882,000USD211,712,000USD-56,536,000USD-104,046,000USD
    Begin Period Cash Flow942,842,000USD755,127,000USD724,531,000USD587,276,000USD649,158,000USD437,446,000USD493,982,000USD598,028,000USD
    End Period Cash Flow1,311,679,000USD942,842,000USD755,127,000USD724,531,000USD587,276,000USD649,158,000USD437,446,000USD493,982,000USD
    Other Cashflows From Investing Activities-7,937,000USD-853,000USD-10,920,000USD103,325,000USD-24,641,000USD89,643,000USD24,192,000USD-10,000USD
    Other Cashflows From Financing Activities-56,854,000USD-31,460,000USD-85,794,000USD-85,378,000USD2,991,000USD27,275,000USD-101,198,000USD-13,054,000USD
    Unclassified Operating Cash Flow48,738,000USD56,096,000USD-44,981,000USD-52,087,000USD-15,608,000USD-888,907,000USD-82,760,000USD-68,378,000USD
    Unclassified Investing Cash Flow-285,193,000USD98,271,000USD108,278,000USD17,634,000USD143,866,000USD-31,916,000USD-18,380,000USD50,000,000USD
    Unclassified Financing Cash Flow14,460,000USD77,560,000USD143,386,000USD138,666,000USD49,194,000USD64,995,000USD85,360,000USD35,919,000USD
    Sale Purchase Of Stock—-77,560,000USD-76,319,000USD-54,283,000USD-45,805,000USD-50,000,000USD-42,680,000USD-35,919,000USD
    Change To Liabilities———59,018,000USD12,353,000USD-93,896,000USD80,217,000USD47,303,000USD
    Dividends Paid———-15,050,000USD-3,389,000USD-71,913,000USD-11,069,000USD—
    Exchange Rate Changes————-57,000USD-1,150,000USD902,000USD-598,000USD
    Cash And Cash Equivalents Changes————-61,882,000USD211,712,000USD-56,536,000USD-104,046,000USD
    Issuance Of Capital Stock———————0USD
    SourceLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Operating metrics

    No operating metrics are currently published for this company.

    Revenue breakdown

    PeriodDimensionBusiness / regionRevenueCurrencySource
    Q2 2026Quarterly · 2026-06-30ProductALDURAZYME43,539,000USDDisclosure
    Q2 2026Quarterly · 2026-06-30ProductProducts Excluding ALDURAZYME — BRINEURA51,370,000USDDisclosure
    Q2 2026Quarterly · 2026-06-30ProductProducts Excluding ALDURAZYME — GALAFOLD105,748,000USDDisclosure
    Q2 2026Quarterly · 2026-06-30ProductProducts Excluding ALDURAZYME — KUVAN24,444,000USDDisclosure
    Q2 2026Quarterly · 2026-06-30ProductProducts Excluding ALDURAZYME — NAGLAZYME135,255,000USDDisclosure
    Q2 2026Quarterly · 2026-06-30ProductProducts Excluding ALDURAZYME — PALYNZIQ135,167,000USDDisclosure
    Q2 2026Quarterly · 2026-06-30ProductProducts Excluding ALDURAZYME — POMBILITIOPFOLDA30,258,000USDDisclosure
    Q2 2026Quarterly · 2026-06-30ProductProducts Excluding ALDURAZYME — ROCTAVIAN11,713,000USDDisclosure
    Q2 2026Quarterly · 2026-06-30ProductProducts Excluding ALDURAZYME — VIMIZIM194,371,000USDDisclosure
    Q2 2026Quarterly · 2026-06-30ProductProducts Excluding ALDURAZYME — VOXZOGO252,528,000USDDisclosure
    Q2 2026Quarterly · 2026-06-30ProductRoyalty And Other5,315,000USDDisclosure
    Q1 2026Quarterly · 2026-03-31ProductALDURAZYME36,742,000USD0001048477-26-000008
    Q1 2026Quarterly · 2026-03-31ProductProducts Excluding ALDURAZYME — BRINEURA47,104,000USD0001048477-26-000008
    Q1 2026Quarterly · 2026-03-31ProductProducts Excluding ALDURAZYME — KUVAN23,880,000USD0001048477-26-000008
    Q1 2026Quarterly · 2026-03-31ProductProducts Excluding ALDURAZYME — NAGLAZYME130,074,000USD0001048477-26-000008
    Q1 2026Quarterly · 2026-03-31ProductProducts Excluding ALDURAZYME — PALYNZIQ89,558,000USD0001048477-26-000008
    Q1 2026Quarterly · 2026-03-31ProductProducts Excluding ALDURAZYME — ROCTAVIAN2,636,000USD0001048477-26-000008
    Q1 2026Quarterly · 2026-03-31ProductProducts Excluding ALDURAZYME — VIMIZIM210,204,000USD0001048477-26-000008
    Q1 2026Quarterly · 2026-03-31ProductProducts Excluding ALDURAZYME — VOXZOGO219,880,000USD0001048477-26-000008
    Q1 2026Quarterly · 2026-03-31ProductRoyalty And Other6,130,000USD0001048477-26-000008
    FY 2025Yearly · 2025-12-31ProductALDURAZYME208,508,000USD0001048477-26-000004
    FY 2025Yearly · 2025-12-31ProductProducts Excluding ALDURAZYME — BRINEURA186,397,000USD0001048477-26-000004
    FY 2025Yearly · 2025-12-31ProductProducts Excluding ALDURAZYME — KUVAN99,530,000USD0001048477-26-000004
    FY 2025Yearly · 2025-12-31ProductProducts Excluding ALDURAZYME — NAGLAZYME485,400,000USD0001048477-26-000004
    FY 2025Yearly · 2025-12-31ProductProducts Excluding ALDURAZYME — PALYNZIQ433,310,000USD0001048477-26-000004
    FY 2025Yearly · 2025-12-31ProductProducts Excluding ALDURAZYME — ROCTAVIAN35,640,000USD0001048477-26-000004
    FY 2025Yearly · 2025-12-31ProductProducts Excluding ALDURAZYME — VIMIZIM792,051,000USD0001048477-26-000004
    FY 2025Yearly · 2025-12-31ProductProducts Excluding ALDURAZYME — VOXZOGO926,923,000USD0001048477-26-000004
    FY 2025Yearly · 2025-12-31ProductRoyalty And Other53,494,000USD0001048477-26-000004
    Q3 2025Quarterly · 2025-09-30ProductALDURAZYME53,709,000USD0001048477-25-000107
    Q3 2025Quarterly · 2025-09-30ProductProducts Excluding ALDURAZYME — BRINEURA47,953,000USD0001048477-25-000107
    Q3 2025Quarterly · 2025-09-30ProductProducts Excluding ALDURAZYME — KUVAN24,025,000USD0001048477-25-000107
    Q3 2025Quarterly · 2025-09-30ProductProducts Excluding ALDURAZYME — NAGLAZYME122,025,000USD0001048477-25-000107
    Q3 2025Quarterly · 2025-09-30ProductProducts Excluding ALDURAZYME — PALYNZIQ108,778,000USD0001048477-25-000107
    Q3 2025Quarterly · 2025-09-30ProductProducts Excluding ALDURAZYME — ROCTAVIAN3,180,000USD0001048477-25-000107
    Q3 2025Quarterly · 2025-09-30ProductProducts Excluding ALDURAZYME — VIMIZIM182,755,000USD0001048477-25-000107
    Q3 2025Quarterly · 2025-09-30ProductProducts Excluding ALDURAZYME — VOXZOGO218,387,000USD0001048477-25-000107
    Q3 2025Quarterly · 2025-09-30ProductRoyalty And Other15,321,000USD0001048477-25-000107
    Q2 2025Quarterly · 2025-06-30ProductALDURAZYME56,437,000USD0001048477-25-000090
    Q2 2025Quarterly · 2025-06-30ProductProducts Excluding ALDURAZYME — BRINEURA48,692,000USD0001048477-25-000090
    Q2 2025Quarterly · 2025-06-30ProductProducts Excluding ALDURAZYME — KUVAN27,034,000USD0001048477-25-000090
    Q2 2025Quarterly · 2025-06-30ProductProducts Excluding ALDURAZYME — NAGLAZYME128,867,000USD0001048477-25-000090
    Q2 2025Quarterly · 2025-06-30ProductProducts Excluding ALDURAZYME — PALYNZIQ105,938,000USD0001048477-25-000090
    Q2 2025Quarterly · 2025-06-30ProductProducts Excluding ALDURAZYME — ROCTAVIAN9,199,000USD0001048477-25-000090
    Q2 2025Quarterly · 2025-06-30ProductProducts Excluding ALDURAZYME — VIMIZIM215,424,000USD0001048477-25-000090
    Q2 2025Quarterly · 2025-06-30ProductProducts Excluding ALDURAZYME — VOXZOGO221,391,000USD0001048477-25-000090
    Q2 2025Quarterly · 2025-06-30ProductRoyalty And Other12,428,000USD0001048477-25-000090
    Q1 2025Quarterly · 2025-03-31ProductALDURAZYME48,977,000USD0001048477-26-000008
    Q1 2025Quarterly · 2025-03-31ProductBRINEURA40,362,000USD0001048477-26-000008
    Q1 2025Quarterly · 2025-03-31ProductKUVAN25,136,000USD0001048477-26-000008
    Q1 2025Quarterly · 2025-03-31ProductNAGLAZYME — PALYNZIQ93,269,000USD0001048477-26-000008
    Q1 2025Quarterly · 2025-03-31ProductNAGLAZYME — ROCTAVIAN10,510,000USD0001048477-26-000008
    Q1 2025Quarterly · 2025-03-31ProductNAGLAZYME — Royalty And Other124,791,000USD0001048477-26-000008
    Q1 2025Quarterly · 2025-03-31ProductVIMIZIM188,346,000USD0001048477-26-000008
    Q1 2025Quarterly · 2025-03-31ProductVOXZOGO213,754,000USD0001048477-26-000008
    FY 2024Yearly · 2024-12-31ProductALDURAZYME183,887,000USD0001048477-26-000004
    FY 2024Yearly · 2024-12-31ProductProducts Excluding ALDURAZYME — BRINEURA169,083,000USD0001048477-26-000004
    FY 2024Yearly · 2024-12-31ProductProducts Excluding ALDURAZYME — KUVAN120,902,000USD0001048477-26-000004
    FY 2024Yearly · 2024-12-31ProductProducts Excluding ALDURAZYME — NAGLAZYME479,584,000USD0001048477-26-000004
    FY 2024Yearly · 2024-12-31ProductProducts Excluding ALDURAZYME — PALYNZIQ355,047,000USD0001048477-26-000004
    FY 2024Yearly · 2024-12-31ProductProducts Excluding ALDURAZYME — ROCTAVIAN26,066,000USD0001048477-26-000004
    FY 2024Yearly · 2024-12-31ProductProducts Excluding ALDURAZYME — VIMIZIM739,784,000USD0001048477-26-000004
    FY 2024Yearly · 2024-12-31ProductProducts Excluding ALDURAZYME — VOXZOGO735,092,000USD0001048477-26-000004
    FY 2024Yearly · 2024-12-31ProductRoyalty And Other44,470,000USD0001048477-26-000004
    Q2 2024Quarterly · 2024-06-30ProductALDURAZYME38,558,000USD0001048477-25-000090
    Q2 2024Quarterly · 2024-06-30ProductProducts Excluding ALDURAZYME — BRINEURA45,309,000USD0001048477-25-000090
    Q2 2024Quarterly · 2024-06-30ProductProducts Excluding ALDURAZYME — KUVAN28,551,000USD0001048477-25-000090
    Q2 2024Quarterly · 2024-06-30ProductProducts Excluding ALDURAZYME — NAGLAZYME132,049,000USD0001048477-25-000090
    Q2 2024Quarterly · 2024-06-30ProductProducts Excluding ALDURAZYME — PALYNZIQ88,291,000USD0001048477-25-000090
    Q2 2024Quarterly · 2024-06-30ProductProducts Excluding ALDURAZYME — ROCTAVIAN7,432,000USD0001048477-25-000090
    Q2 2024Quarterly · 2024-06-30ProductProducts Excluding ALDURAZYME — VIMIZIM178,016,000USD0001048477-25-000090
    Q2 2024Quarterly · 2024-06-30ProductProducts Excluding ALDURAZYME — VOXZOGO183,923,000USD0001048477-25-000090
    Q2 2024Quarterly · 2024-06-30ProductRoyalty And Other9,900,000USD0001048477-25-000090
    Q1 2024Quarterly · 2024-03-31ProductALDURAZYME35,262,000USD0001048477-25-000051
    Q1 2024Quarterly · 2024-03-31ProductProducts Excluding ALDURAZYME — BRINEURA39,047,000USD0001048477-25-000051
    Q1 2024Quarterly · 2024-03-31ProductProducts Excluding ALDURAZYME — KUVAN35,910,000USD0001048477-25-000051
    Q1 2024Quarterly · 2024-03-31ProductProducts Excluding ALDURAZYME — NAGLAZYME105,629,000USD0001048477-25-000051
    Q1 2024Quarterly · 2024-03-31ProductProducts Excluding ALDURAZYME — PALYNZIQ75,709,000USD0001048477-25-000051
    Q1 2024Quarterly · 2024-03-31ProductProducts Excluding ALDURAZYME — ROCTAVIAN849,000USD0001048477-25-000051
    Q1 2024Quarterly · 2024-03-31ProductProducts Excluding ALDURAZYME — VIMIZIM192,520,000USD0001048477-25-000051
    Q1 2024Quarterly · 2024-03-31ProductProducts Excluding ALDURAZYME — VOXZOGO152,889,000USD0001048477-25-000051
    Q1 2024Quarterly · 2024-03-31ProductRoyalty And Other11,018,000USD0001048477-25-000051
    Q4 2023Quarterly · 2023-12-31ProductALDURAZYME42,715,000USDLegacy provider
    Q4 2023Quarterly · 2023-12-31ProductProducts Excluding ALDURAZYME — BRINEURA43,645,000USDLegacy provider
    Q4 2023Quarterly · 2023-12-31ProductProducts Excluding ALDURAZYME — KUVAN36,720,000USDLegacy provider
    Q4 2023Quarterly · 2023-12-31ProductProducts Excluding ALDURAZYME — NAGLAZYME98,252,000USDLegacy provider
    Q4 2023Quarterly · 2023-12-31ProductProducts Excluding ALDURAZYME — PALYNZIQ87,814,000USDLegacy provider
    Q4 2023Quarterly · 2023-12-31ProductProducts Excluding ALDURAZYME — ROCTAVIAN2,667,000USDLegacy provider
    Q4 2023Quarterly · 2023-12-31ProductProducts Excluding ALDURAZYME — VIMIZIM175,600,000USDLegacy provider
    Q4 2023Quarterly · 2023-12-31ProductProducts Excluding ALDURAZYME — VOXZOGO145,735,000USDLegacy provider
    Q4 2023Quarterly · 2023-12-31ProductRoyalty And Other13,059,000USDLegacy provider
    FY 2023Yearly · 2023-12-31ProductALDURAZYME131,248,000USD0001048477-26-000004
    FY 2023Yearly · 2023-12-31ProductProducts Excluding ALDURAZYME — BRINEURA161,889,000USD0001048477-26-000004
    FY 2023Yearly · 2023-12-31ProductProducts Excluding ALDURAZYME — KUVAN180,767,000USD0001048477-26-000004
    FY 2023Yearly · 2023-12-31ProductProducts Excluding ALDURAZYME — NAGLAZYME420,292,000USD0001048477-26-000004
    FY 2023Yearly · 2023-12-31ProductProducts Excluding ALDURAZYME — PALYNZIQ303,919,000USD0001048477-26-000004
    FY 2023Yearly · 2023-12-31ProductProducts Excluding ALDURAZYME — ROCTAVIAN3,489,000USD0001048477-26-000004
    FY 2023Yearly · 2023-12-31ProductProducts Excluding ALDURAZYME — VIMIZIM701,053,000USD0001048477-26-000004
    FY 2023Yearly · 2023-12-31ProductProducts Excluding ALDURAZYME — VOXZOGO469,881,000USD0001048477-26-000004
    FY 2023Yearly · 2023-12-31ProductRoyalty And Other46,688,000USD0001048477-26-000004

    Periods follow company fiscal calendars. Quarterly, annual and year-to-date amounts are shown separately. Missing values are not zero. Data may be delayed, incomplete or corrected; follow the disclosure links to verify figures.